论文部分内容阅读
本文报道了病毒唑及其与干扰素联合对23例慢乙肝近、远期抗病毒效应观察结果,并与12例未经抗病毒治疗的慢乙肝作对照(Ⅲ组),其中病毒唑与干扰素联合组(I组)12例,病毒唑组(Ⅱ组)11例。近期HBeAg、DNAP及HBV·DNA阴转率,I组分别为(41.6％、55.5％及28.s％,Ⅱ组45.4％、100％及33.3％,Ⅲ组8.3％、16.6％及8.3％。远期HBeAg及DNAP阴转率在I组分别为70％、83.7％。Ⅱ组60％、100％,Ⅲ组8.3％,50％。综合抗病毒效应,近期有效率在I、Ⅱ、Ⅲ组分别为50％、72.7％及16.6％。远期则分别为70％、55.5％及8.3％。无一例出现毒副反应。均完成疗程。上述结果提示病毒唑及其与干扰素联合对慢乙肝均有一定抗病毒效应,联合应用并不优于单一用药,但毒副反应也未见加重,而且病毒唑药源较方便,使用较安全,值得进一步研究。
This paper reports the results of ribavirin and its combination with interferon on 23 patients with chronic hepatitis B in the near and long-term antiviral effects, and compared with 12 cases of chronic hepatitis B without antiviral therapy (group Ⅲ), of which ribavirin and interference 12 cases in the combination group (group I) and 11 cases in the group Ribavirin (group Ⅱ). The recent negative rates of HBeAg, DNAP and HBV DNA were 41.6%, 55.5% and 28.s% in group I, 45.4%, 100% and 33.3% in group I, and 8.3%, 16.6% and 8.3% in group III, respectively. Long-term HBeAg and DNAP negative conversion rate in the I group were 70%, 83.7% .Ⅱ group 60%, 100%, Ⅲ group 8.3%, 50% .Integral antiviral effect, the recent efficiency in the I, Ⅱ, Ⅲgroup Respectively, 50%, 72.7% and 16.6%, respectively, in the long term were 70%, 55.5% and 8.3%, respectively.No adverse reactions occurred.All the completed treatment.The above results suggest that ribavirin and interferon combined with chronic hepatitis B Both have a certain antiviral effect, combined application is not better than a single drug, but no increase in side effects, and ribavirin drug source more convenient and safer, worthy of further study.